<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01443442</url>
  </required_header>
  <id_info>
    <org_study_id>MAC-06-11</org_study_id>
    <nct_id>NCT01443442</nct_id>
  </id_info>
  <brief_title>Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis</brief_title>
  <official_title>A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California College of Optometry at Marshall B. Ketchum University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southern California College of Optometry at Marshall B. Ketchum University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allergic conjunctivitis (AC) afflicts approximately 20% of the US population. Typically,
      patients manifest symptoms in the spring, summer and fall, when airborne allergens are at
      their peak. Patients may also be afflicted year-round, if sensitive to allergens such as dust
      mites or pet dander. Signs and symptoms of allergic conjunctivitis are conjunctival
      hyperemia, ocular itching, conjunctival and eyelid edema, papillary hypertrophy, tearing and
      burning.

      This is a randomized clinical study to evaluate the efficacy of Bepreve® (bepotastine
      besilate 1.5% ophthalmic solution) compared to Alrex® (loteprednol etabonate 0.2%) in the
      treatment of moderate to severe allergic conjunctivitis in patient over the age of 18 years.
      The study will be a two-week study with four visits. Ocular signs (eye redness( and symptoms
      (itching) will be monitored as outcome variables.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigator and Study Center:

      Judy Tong, OD Eye Care Center Southern California College of Optometry

      Test Product, Dose and Mode of Administration:

      Bepreve (bepotastine besilate ophthalmic solution) 1.5% bid ou vs. Alrex (loteprednol
      etabonate ophthalmic suspension) 0.2% qid ou

      Study Title:

      A Single-Center, Masked, Randomized Study Comparing Bepreve (bepotastine besilate) 1.5% - H1
      Specific Antihistamine vs. Alrex (loteprednol etabonate) 0.2% - Corticosteroid in Subjects
      with Moderate to Severe Allergic Conjunctivitis

      Primary Objective(s):

      The primary objective of this study is to compare the efficacy of Bepreve (bepotastine
      besilate) 1.5% ophthalmic solution compared to Alrex (loteprednol etabonate) 0.2% in the
      treatment of moderate to severe allergic conjunctivitis in patients over the age of 18 years
      of age

      Study Design:

      Interventional, Randomized, Parallel Arm, Investigator Masked

      Study Population:

      Subjects over the age of 18 years of age with moderate to severe allergic conjunctivitis.

      Duration of Treatment: 14 days

      Efficacy Assessments: Itching, Bulbar conjunctival injection, Bulbar conjunctival chemosis

      Safety Assessments: N/A
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Ocular Itching at 14 Days</measure>
    <time_frame>Change from Baseline in Ocular Itching at 14 Days</time_frame>
    <description>Ocular Itching Scale. Scale is 0 - 4 in 0.5 scale unit increments. 0 equals no Itch. 4 equals most severe itch. No calculation details are necessary as the change is calculated as the latest time point minus the earliest time point.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Bepreve</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.5% bepotastine besilate, drops, twice per day, for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alrex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with 0.2 % loteprednol etabonate, drops, four times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bepotastine besilate, 1.5%</intervention_name>
    <description>Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days</description>
    <arm_group_label>Bepreve</arm_group_label>
    <other_name>Bepreve</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol etabonate</intervention_name>
    <description>Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days</description>
    <arm_group_label>Alrex</arm_group_label>
    <other_name>Alrex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe allergic subjects (≥ 2.5 on a 0.0 to 4.0 itching scale AND

             &gt; grade 2.0 bulbar redness using validated (Efron) scale)

          -  Must be able to understand and sign an informed consent form that has been approved by
             the Institutional Review Board (IRB).

          -  Can comply with instillation of study drug

          -  Must be able to comply with the visit schedule and other requirements of the study.

        Exclusion Criteria:

          -  Subjects who use daily wear (5-7 days / week, 6-16 hours/day)25 disposable soft
             hydrogel or silicone hydrogel contact lenses will be included in the study if they
             have been consistently wearing the same brand and have been using the same care
             solution for one month or longer. They will be asked to not wear their soft contact
             lenses to the eligibility visit (three days of no lens wear) and be willing to
             discontinue lens wear during the two weeks of the study because of the incompatibility
             of medicated eye drop instillation with contact lens wear and the potential
             confounding effect of contact lenses and care solutions.

          -  Active inflammation of the cornea, iris, anterior chamber

          -  Active or suspected herpetic eye disease (simplex, vaccinia, varicella)

          -  Active or suspected mycobacterial or acanthamoeba infection

          -  Active for suspected fungal disorders of the eye

          -  Persistent and significant dry eye syndrome

          -  Known allergy, contraindications or hypersensitivity to loteprednol, bepotastine, or
             its components

          -  Pregnancy or breast-feeding

          -  Use of topical eye drops, topical or systemic antihistamines, topical, nasal or
             systemic corticosteroids, immunosuppressive or immunomodulating agents, decongestants,
             aspirin, or non-steroidal antiinflammatory (NSAIDs) during the two weeks prior to the
             study.

          -  Participation in any other study within 30 days of this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judy Tong, OD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern California College of Optometry at Marshall B. Ketchum University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Car Center, Southern California college of Optometry</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Care Center, Southern Caalifornia College of Optometry</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92831</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 27, 2011</study_first_submitted>
  <study_first_submitted_qc>September 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2011</study_first_posted>
  <results_first_submitted>January 26, 2016</results_first_submitted>
  <results_first_submitted_qc>July 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2019</results_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Conjunctivitis</keyword>
  <keyword>Allergic</keyword>
  <keyword>Bepotastine besilate</keyword>
  <keyword>Loteprednol etabonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
    <mesh_term>Bepotastine besilate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bepreve</title>
          <description>1.5% bepotastine besilate, drops, twice per day, for two weeks
bepotastine besilate, 1.5%: Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Alrex</title>
          <description>treatment with 0.2 % loteprednol etabonate, drops, four times per day
Loteprednol etabonate: Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bepreve</title>
          <description>1.5% bepotastine besilate, drops, twice per day, for two weeks
bepotastine besilate, 1.5%: Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Alrex</title>
          <description>treatment with 0.2 % loteprednol etabonate, drops, four times per day
Loteprednol etabonate: Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" spread="16.3"/>
                    <measurement group_id="B2" value="53.0" spread="13.0"/>
                    <measurement group_id="B3" value="51.1" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Ocular Itching at 14 Days</title>
        <description>Ocular Itching Scale. Scale is 0 - 4 in 0.5 scale unit increments. 0 equals no Itch. 4 equals most severe itch. No calculation details are necessary as the change is calculated as the latest time point minus the earliest time point.</description>
        <time_frame>Change from Baseline in Ocular Itching at 14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bepreve</title>
            <description>1.5% bepotastine besilate, drops, twice per day, for two weeks
bepotastine besilate, 1.5%: Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Alrex</title>
            <description>treatment with 0.2 % loteprednol etabonate, drops, four times per day
Loteprednol etabonate: Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Ocular Itching at 14 Days</title>
          <description>Ocular Itching Scale. Scale is 0 - 4 in 0.5 scale unit increments. 0 equals no Itch. 4 equals most severe itch. No calculation details are necessary as the change is calculated as the latest time point minus the earliest time point.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="0.53"/>
                    <measurement group_id="O2" value="1.82" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bepreve</title>
          <description>1.5% bepotastine besilate, drops, twice per day, for two weeks
bepotastine besilate, 1.5%: Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Alrex</title>
          <description>treatment with 0.2 % loteprednol etabonate, drops, four times per day
Loteprednol etabonate: Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jerry R. Paugh, OD, PhD</name_or_title>
      <organization>SCCO at MBKU</organization>
      <phone>714-449-7487</phone>
      <email>jpaugh@ketchum.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

